CMDh: Dexamethasone for the treatment of COVID-19
CMDh has published a summary RMP for medicinal products containing dexamethasone for the treatment of COVID-19. The CMDh agreed that the RMP can be implemented (in this specific case) as updated or a new RMP for concerned products via a type IB variation C.I.11.z, using variation worksharing, where possible. The CMDh March Press Release covers this topic further.
Summary of risk management plan for dexamethasone for treatment of coronavirus disease 2019